Processing

Please wait...

Settings

Settings

Goto Application

1. EP3271022 - HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF

Office
European Patent Office
Application Number 16765900
Application Date 21.03.2016
Publication Number 3271022
Publication Date 24.01.2018
Publication Kind A4
IPC
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
C07K 14/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C12N 15/13
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
42viral
C07K 16/1045
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
1036Retroviridae, e.g. leukemia viruses
1045Lentiviridae, e.g. HIV, FIV, SIV
C07K 2299/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2299Coordinates from 3D structures of peptides, e.g. proteins or enzymes
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
54F(ab')2
C07K 2317/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
55Fab or Fab'
Applicants UNIV DUKE
UNIV MARYLAND
Inventors HAYNES BARTON F
LIAO HUA-XIN
MOODY M ANTHONY
WILLIAMS LATONYA
WIEHE KEVIN J
OFEK GILAD ADI
Designated States
Priority Data 201562135309 19.03.2015 US
201562191054 10.07.2015 US
201562191095 10.07.2015 US
201562222057 22.09.2015 US
201562260100 25.11.2015 US
201562261233 30.11.2015 US
Title
(DE) HIV-1-NEUTRALISIERENDE ANTIKÖRPER UND VERWENDUNGEN DAVON
(EN) HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF
(FR) ANTICORPS NEUTRALISANT LE VIH-1 ET LEURS UTILISATIONS
Abstract
(EN) The invention is directed to HIV- 1 neutralizing antibodies and methods for their uses.
(FR) La présente invention concerne des anticorps neutralisant le VIH-1 et des procédés d'utilisation correspondants.